1Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration[ J]. Annu Rev Neurosci, 1997,20 : 125 - 156.
2Masson J, Sagne C, Hamon M, et al. Neurotransmitter transporters in the central nervous system [ J ]. Pharmacol Rev, 1999,51 (3) :439 -464.
3Ciliax B J, Heilman C, Demchyshyn LL, et al. The dopamine transporter: immunochemical characterization and localization in brain [J]. J Neurosci,1995,15(3 Pt 1 ) :1714 - 1723.
4van Dyck CH, Seibyl JP, Malison RT, et al. Age - related decline in dopamine transporters : analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries [ J ]. Am J Geriatr Psychiatry,2002,10 ( 1 ) :36 - 43.
5Prunier C, Bezard E, Montharu J, et al. Presymptomatic diagnosis of experimental Parkinsonism with ^123I - PE2I SPECT [ J]. Neuro- image,2003,19(3) :810 -816.
6Emond P, Guilloteau D, Chalon S. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter [ J]. CNS Neurosci Ther,2008,14( 1 ) :47 - 64.
7Chitneni SK, Garreau L, Cleynhens B, et al. Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [ (18) F] FECT [ J]. Nucl ned Biol,2008,35 ( 1 ) :75 - 82.
8Wuest F, Berndt M, Strobel K, et al. Synthesis and radiopharma-cological characterization of 2beta - carbo - 2' - [ 18F] fluoroe- thoxy - 3beta - (4 - bromo - phenyl) tropane ( [ 18F] MCL - 322) as a PET radiotracer for imaging the dopamine transporter (DAT) [ J ]. Bioorg Med Chem,2007,15 ( 13 ) :4511 - 4519.
9Saba W, Valette H, Schollhorn - Peyronneau MA, et al. [ 11CLBT - 999 : a suitable radioligand for investigation of extra - striatal dopamine transporter with PET [ J]. Synapse,2007 ,61 ( 1 ) :17 - 23.
10Laine TP, Ahonen A, Tomiainen P, et al. Dopamine transporters increase in human brain after alcohol withdrawal [ J ]. Mol Psychiatry, 1999,4(2) :189 - 191,104 - 105.
